Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal
AI Briefing
- • AstraZeneca secures rights to PDE3/4 inhibitor for chronic obstructive pulmonary disease (COPD) in $2.1 billion deal.
- • The treatment aims to improve lung function and slow disease progression in patients with COPD.
- • SinoPharm Group will develop and commercialize the drug globally, with AstraZeneca providing additional support.
Context
Astrazeneca has acquired a PDE3/4 inhibitor for chronic obstructive pulmonary disease in a deal with Sino. The deal is valued at $2.1 billion.
The acquisition of the PDE3/4 inhibitor is significant for Astrazeneca as it expands the company's portfolio for treating COPD.
Advertisement